Putting Capital to Work

In 2022, Pfizer has put capital to work as we strive to fuel future growth and return cash dividends directly to investors.

In the first six months of 2022, the company re-invested more than $12 billion in total into innovation, consisting of $5.1 billion in its R&D innovation pipeline and more than $7 billion in completed business development transactions.

In addition, $4.5 billion in cash dividends was returned to shareholders by August 2022. On Sept. 6, Pfizer paid a cash dividend of $0.40 per share to investors. See some key dates below.

*Transactions remain subject to certain closing conditions.

Join Pfizer Investor Insights

Sign up to receive important updates about Pfizer, how we’re innovating for patients and delivering value for shareholders. Email updates will also provide exciting opportunities for individual shareholders to hear from our leadership and experts.

I would like to receive information, updates, and hear from leadership regarding Pfizer Investor Insights and other investor relations initiatives in accordance with Pfizer’s Privacy Policy.